The estimated Net Worth of Robert J. Hombach is at least $19 Milion dollars as of 11 November 2021. Mr. Hombach owns over 80,000 units of Biomarin Pharmaceutical stock worth over $18,575,298 and over the last 14 years he sold BMRN stock worth over $0. In addition, he makes $471,895 as Independent Director at Biomarin Pharmaceutical.
Sign up
Mr. Hombach BMRN stock SEC Form 4 insiders trading
Robert has made over 6 trades of the Biomarin Pharmaceutical stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 80,000 units of BMRN stock worth $192,000 on 11 November 2021.
The largest trade he's ever made was buying 80,000 units of Biomarin Pharmaceutical stock on 11 November 2021 worth over $192,000. On average, Robert trades about 6,585 units every 72 days since 2010. As of 11 November 2021 he still owns at least 219,100 units of Biomarin Pharmaceutical stock.
You can see the complete history of Mr. Hombach stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Hombach biography
Robert J. Hombach, CPA, is Independent Director of the Company. Mr. Hombach joined our Board in September 2017 and currently serves as the Chair of the Audit Committee. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc., a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off in June 2015. From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. Prior to that, he served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the board of CarMax, Inc., a public company and in 2018 was appointed to the board of Aptinyx Inc., a public biopharmaceutical company. Previously, he served on the board of Naurex, Inc., a private pharmaceutical company acquired by Allergan in 2015. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management, and a B.S. in Finance cum laude from the University of Colorado..
What is the salary of Robert Hombach?
As the Independent Director of Biomarin Pharmaceutical, the total compensation of Robert Hombach at Biomarin Pharmaceutical is $471,895. There are 11 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
How old is Robert Hombach?
Robert Hombach is 54, he's been the Independent Director of Biomarin Pharmaceutical since 2017. There are 16 older and 6 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
What's Robert Hombach's mailing address?
Robert's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Insiders trading at Biomarin Pharmaceutical
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
What does Biomarin Pharmaceutical do?
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
What does Biomarin Pharmaceutical's logo look like?
Complete history of Mr. Hombach stock trades at Biomarin Pharmaceutical, Baxter International, Carmax Inc a Aptinyx Inc
Biomarin Pharmaceutical executives and stock owners
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:
-
Jean-Jacques Bienaime,
Chairman of the Board, Chief Executive Officer -
Henry Fuchs,
President - Worldwide Research & Development -
Jeff Ajer,
Executive Vice President, Chief Commercial Officer -
Jean-Jacques Bienaime M.B.A., MBA,
Chairman & CEO -
G. Eric Davis,
Executive Vice President, General Counsel, Secretary -
Dr. Henry J. Fuchs,
Pres of Worldwide R&D -
Dr. C. Greg Guyer Ph.D.,
CTO and Exec. VP of Global Manufacturing & Technical Operations -
Jeffrey Robert Ajer,
Exec. VP & Chief Commercial Officer -
Brian R. Mueller,
Exec. VP of Fin. & CFO -
Richard Meier,
Lead Independent Director -
Elaine Heron,
Independent Director -
Robert Hombach,
Independent Director -
Alan Lewis,
Independent Director -
Michael Grey,
Independent Director -
V. Bryan Lawlis,
Independent Director -
David Pyott,
Independent Director -
Dennis Slamon,
Independent Director -
Willard Dere,
Independent Director -
Elizabeth Anderson,
Independent Director -
Lon Cardon,
Chief Scientific Strategy Officer -
Andrea Acosta,
Chief Accounting Officer, Group Vice President -
C. Greg Guyer,
Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations -
Brian Mueller,
Chief Financial Officer, Executive Vice President -
Dr. Brinda Balakrishnan M.D., Ph.D.,
Group VP of Corp. & Bus. Devel. -
Philip Lo Scalzo,
Sr. VP & Chief Compliance Officer -
George Eric Davis,
Exec. VP, Gen. Counsel & Sec. -
Traci McCarty,
VP of Investor Relations -
Andrea L. Acosta,
Group VP & Chief Accounting Officer -
Daniel K Spiegelman,
EVP, Chief Financial Officer -
Athena Countouriotis,
Director -
Mark J Enyedy,
Director -
Barbara W. Bodem,
Director -
Robert Baffi,
President, Global Mfg/Tech Ops -
Cristin Hubbard,
EVP, Chief Commercial Officer -
Kathryn E Falberg,
Director -
William D Young,
Director -
Pierre Lapalme,
Director -
Jeffrey Landau,
Sr. Vice President, Admin. -
Gwynn Williams,
Director -
Steve Aselage,
SVP, Global Commercial Ops -
Christopher M Starr,
Sr. VP, Scientific Operations -
Franz L Cristiani,
Director -
Jeffrey H Cooper,
Chief Financial Officer -
Joseph Iii Klein,
Director -
Emil D Kakkis,
SVP, Business Operations -
Kenneth Bate,
Director -
Mark Wood,
VP, Human Resources -
John Urquhart,
Director -
Erich Sager,
Director -
Stuart J Swiedler,
SVP, Clinical Affairs -
Fredric D Price,
Chief Executive Officer -
Vijay B Samant,
Director -
Maykin Ho,
Director -
Mark J Alles,
Director -
Erin Burkhart,
GVP, Chief Accounting Officer -
Alexander Hardy,
Chief Executive Officer